ClinicalTrials.gg
TerminatedNCT06446063Updated May 8, 2026

Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.

An observational study in Vitiligo, sponsored by Pierre Fabre Dermo Cosmetique. Terminated at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Pierre Fabre Dermo Cosmetique (part of Pierre Fabre) · Observational

Why this study was terminated
Lack of recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
19
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies in Vitiligo with a site in France — 8 open to participants now, 14 under way, 6 of them phase 3. Vitiligo · France.

Started
2024
with 3 others
Observational
7 of 45
3 open now
Registered
39th of 45
by date

Among the 45 studies in Vitiligo with a site in France, this one is one of 4 that started in 2024, is one of 7 observational ones, and was the 39th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

8 of the 45 studies in Vitiligo with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Vitiligo with a site in France, or all of them as a file.
02

Study summary

Vitiligo is an autoimmune depigmentation disorder affecting 0.5 to 1% of the population worldwide. Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in the epidermis, mainly resulting from the activation of immune cells in a genetically predisposed patient.

Despite major advances in the understanding of the mechanisms of the disease, the treatment remains challenging. Different treatment strategies could lead to cosmetically acceptable repigmentation (>75%), particularly on face and neck. However, after repigmentation, the risk of relapse is estimated at nearly 40% during the first year after stopping treatment.

To date, long-term management remains a challenge. With their topical product RV5098A adapted for patients with vitiligo, Pierre Fabre Laboratories hypothesize that it could be effective in maintaining pigmentation of previously repigmented lesions in adults with facial vitiligo.

03

Conditions studied

  • Vitiligo

Browse trials for

Keywords

  • Vitiligo
  • Adults
  • Face
  • Repigmented
  • Maintenance of repigmentation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be enrolled from the investigator's outpatient's reception and/or from the database of the centre. The subjects corresponding to eligibility criteria may receive a phone call, a letter or an e-mail proposing to participate to the clinical study.

Eligibility criteria

Inclusion Criteria:

Criteria related to the population:

- Subject aged between 18 and 75 years included.

Criteria related to the disease:

  • Subject with facial vitiligo, regardless of its duration.
  • having a sufficient repigmentation rate of the vitiligo after repigmenting treatment

Criteria related to treatments and/or products:

- Subject responder to a repigmenting treatment

Non-inclusion Criteria:

Criteria related to the diseases / skin condition:

  • Subject with active vitiligo.
  • Subject with spontaneous repigmentation without treatment.
  • Subject having other dermatological condition, an acute, chronic, or progressive disease or history of disease liable to interfere with the study assessments or considered by the Investigator hazardous for the subject or incompatible with the study requirements.

Criteria related to treatments and/or products:

  • Systemic immunomodulatory treatment taken for another pathology, before inclusion, on-going or planned to be established during the study.
  • Any topical immunomodulatory treatment applied on the face for another pathology, on-going or planned to be established during the study.
  • Any other topical or systemic treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy according to the investigator's assessment.
  • Any dietary supplement for vitiligo within 4 weeks before the inclusion visit or planned to be established during the study.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
19 participants (actual)
Patient registry
No

Groups and cohorts

  • Treated group

    Other: Test product

  • Control group

    Other: Control Product

Interventions

  • OtherTest product

    Twice daily applications The product is applied to the entire face.

  • OtherControl Product

    Twice daily applications The product is applied to the entire face.

06

What researchers measure

Primary outcomes

  1. Efficacy of the test product RV5098A on the maintenance of pigmentation by the global evolution of facial vitiligo

    assessed by the investigator on the face on a 7-point scale (from significant worsening to significant improvement)

    Time frame: assessed after 24 weeks of use

Secondary outcomes

  1. Efficacy of the test product RV5098A on the maintenance of pigmentation by the global evolution of facial vitiligo assessed by the investigator

    assessed by the investigator on the face on a 7-point scale (from significant worsening to significant improvement)

    Time frame: assessed after 12 weeks of use

  2. Efficacy of the test product RV5098A on the maintenance of pigmentation by the global evolution of facial vitiligo assessed by the subject

    assessed by the subject on the face on a 7-point scale (from very much worse to very much improved)

    Time frame: assessed after 12 and 24 weeks of use and monthly at home

  3. Efficacy of the test product RV5098A on the maintenance of pigmentation by the severity of facial vitiligo by the investigator

    assessed by the investigator on the face on a vitiligo severity scale from 0 (absent) to 3 (complete depigmentation)

    Time frame: assessed at baseline and after 12 and 24 weeks of use.

  4. Efficacy of the test product RV5098A on the maintenance of pigmentation by the extent of facial vitiligo

    assessed by the investigator on the face with score of extent of vitiligo

    Time frame: assessed at baseline and after 12 and 24 weeks of use.

  5. Efficacy of the test product RV5098A on the maintenance of pigmentation by the severity of facial vitiligo by the subject

    assessed by the subject on the face on a 5-point scale (from no vitiligo to very severe)

    Time frame: assessed at baseline, after 12 and 24 weeks of use and monthly at home

  6. Efficacy of the test product RV5098A on the maintenance of pigmentation by the impact on quality of life assessed by the patient

    assessed by the subject with quality-of-life questionnaire

    Time frame: assessed at baseline, after 12 and 24 weeks of use

  7. Efficacy of the test product RV5098A on the maintenance of pigmentation by imaging quantification.

    Measurement of depigmentation surface on a target lesion of the face by the investigator.

    Time frame: assessed at baseline, after 12 and 24 weeks of use.

  8. Cosmetic satisfaction and perceived effects as regards to the use of the test product RV5098A by Cosmetic acceptability questionnaire assessed by the patient

    A questionnaire with a scale from 0 to 10 responding to statements about the sensorial experience and effect of the product (0=not at all agree, 10=completely agree).

    Time frame: assessed after 12 and 24 weeks of use.

  9. Global tolerance of the test product RV5098A assessed by the investigator.

    assessed by the investigator with 5-point scale (from bad to excellent)

    Time frame: assessed after 24 weeks of use.

  10. Compliance of the subjects to the test product RV5098A

    The subject will report his/her compliance in a subject's diary

    Time frame: through study completion, 6 months

07

Study locations

1 site
  • COSDERMA
    Bordeaux, Gironde 33000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Oct 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
Jun 6, 2024
StartActual
May 23, 2024
Primary completionActual
Oct 31, 2025
CompletionActual
Oct 31, 2025
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06446063
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
May 23, 2024
Primary completion
Oct 31, 2025
Completion
Oct 31, 2025
Last update
May 8, 2026

Study contacts

Julien SENESCHAL, Pr
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion